GTO ID | GTC0619 |
Trial ID |
2004-003934-32
|
Disease |
Familial Hypercholesterolemia
|
Altered gene | APOB |
Therapeutic/Target gene | Target gene |
Therapy | ASO |
Treatment | ISIS 301012|mipomersen sodium|Kynamro |
Location approved | US, Mexico, Argentina, South Korea |
Phase | Phase2 |
Recruitment status | Completed |
Title | A Phase II, Randomized, Double Blind, Placebo-Controlled Study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 301012 Administered to Hypercholesterolemic Subjects. |
Year | 2005 |
Country | Germany |
Company sponsor | Isis Pharmaceuticals Inc. |